Resources from the same session
LBA6 - EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC)
Presenter: Thomas Powles
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
LBA7 - Nivolumab plus gemcitabine-cisplatin versus gemcitabine-cisplatin alone for previously untreated unresectable or metastatic urothelial carcinoma: Results from the phase III CheckMate 901 trial
Presenter: Michiel van der Heijden
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA6 and LBA7
Presenter: Andrea Apolo
Session: Presidential 2
Resources:
Slides
Webcast
LBA8 - A randomised phase III trial of induction chemotherapy followed by chemoradiation compared with chemoradiation alone in locally advanced cervical cancer: The GCIG INTERLACE trial
Presenter: Mary McCormack
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
LBA9 - innovaTV 301/ENGOT-cx12/GOG-3057: A global, randomized, open-label, phase III study of tisotumab vedotin vs investigator’s choice of chemotherapy in 2L or 3L recurrent or metastatic cervical cancer
Presenter: Ignace Vergote
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA8 and LBA9
Presenter: Krishnansu Tewari
Session: Presidential 2
Resources:
Slides
Webcast
LBA10 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study
Presenter: Filippo Pietrantonio
Session: Presidential 2
Resources:
Abstract
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Presidential 2
Resources:
Webcast